News Releases

Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center , New York , investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density
July 10, 2023
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral immunotherapy) and TVAX Immunotherapy ® (vaccine-enhanced adoptive T cell therapy).
June 29, 2023
Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responses Generated promising progression-free survival Demonstrated clinical reversal of platinum resistance and refractoriness Phase 3
May 25, 2023
WESTLAKE VILLAGE, Calif. , May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation  (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately
May 15, 2023
Displaying 11 - 20 of 29